Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC (KN035-BTC)

  • STATUS
    Recruiting
  • End date
    Jul 30, 2024
  • participants needed
    480
  • sponsor
    3D Medicines (Sichuan) Co., Ltd.
Updated on 14 July 2022
cancer
systemic therapy
measurable disease
oxaliplatin
gemcitabine
recurrent disease
cholangiocarcinoma
metastatic biliary tract carcinoma
biliary tract cancer

Summary

This is a randomized, open-label, parallel-group multi-center study of Phase 3 study to assess the efficacy and safety of KN035 compared to standard of care (SOC) Gemcitabine-based chemotherapies in the treatment of participants with previously untreated locally advanced or metastatic biliary tract cancer.

The primary hypothesis of this study is that participants will have a longer overall Survival (OS) when treated with combined therapy than SOC.

Details
Condition Biliary Tract Neoplasms
Treatment KN035 plus Gemcitabine & oxaliplatin, Gemcitabine & oxaliplatin
Clinical Study IdentifierNCT03478488
Sponsor3D Medicines (Sichuan) Co., Ltd.
Last Modified on14 July 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Eighteen years and older
Histological or cytological diagnosis of unresectable or metastatic gallbladder cancer or cholangiocarcinoma
Previously untreated with systemic therapy; Subjects who developed recurrent disease >6 months after a sort of adjuvant, neoadjuvant chemotherapy could also be eligible
Liver function Child-Pugh A or B
Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status
Life expectancy of at least 12 weeks
At least one measurable lesion per RECIST 1.1
Adequate organ function

Exclusion Criteria

Specific anti-tumor treatment prior to 4 weeks
more than 50% liver metastasis
Patient with other serious diseases or clinical conditions, including but not limited to uncontrolled active infection etc
History of severe hypersensitivity reaction to any monoclonal antibody or chemistry
Women who are pregnant or in the period of lactation
Patients with an active, known or suspected autoimmune disease. Patients are permitted to enrol if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note